FCM
Farallon Capital Management Portfolio holdings
AUM
$21.3B
This Quarter Return
+22.23%
1 Year Return
+23.12%
3 Year Return
+87.19%
5 Year Return
+183.94%
10 Year Return
+836.54%
AUM
$12.1B
AUM Growth
+$12.1B
(+6%)
Cap. Flow
-$1.14B
Cap. Flow
% of AUM
-9.39%
Top 10 Holdings %
Top 10 Hldgs %
48.07%
Holding
116
New
19
Increased
27
Reduced
27
Closed
22
Top Buys
| 1 |
CELG
Celgene Corp
CELG
|
$795M |
| 2 |
S&P Global
SPGI
|
$192M |
| 3 |
Sherwin-Williams
SHW
|
$165M |
| 4 |
Sea Limited
SE
|
$163M |
| 5 |
WCG
Wellcare Health Plans, Inc.
WCG
|
$151M |
Top Sells
| 1 |
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
|
$616M |
| 2 |
TFCF
Twenty-First Century Fox, Inc. Class B
TFCF
|
$370M |
| 3 |
Equinix
EQIX
|
$315M |
| 4 |
Meta Platforms (Facebook)
META
|
$204M |
| 5 |
Alphabet (Google) Class C
GOOG
|
$202M |
Sector Composition
| 1 | Healthcare | 29.96% |
| 2 | Technology | 22.53% |
| 3 | Communication Services | 18.58% |
| 4 | Industrials | 7.24% |
| 5 | Consumer Discretionary | 6.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Walt Disney
DIS
$213B
| $48.9M | 0.37% | +440,000 | New | +$48.9M |
|
52
NXP Semiconductors
NXPI
$59.2B
| $47.3M | 0.36% | 535,000 | – | – |
|
53
Alnylam Pharmaceuticals
ALNY
$58.5B
| $46.7M | 0.35% | 500,000 -50,000 | -9% | -$4.67M |
|
54
Fate Therapeutics
FATE
$120M
| $43.9M | 0.33% | 2,500,000 +300,000 | +14% | +$5.27M |
|
|
RDUS
55
DELISTED
Radius Health, Inc.
RDUS
| $40.7M | 0.31% | 2,043,149 | – | – |
|
|
SINA
56
DELISTED
Sina Corp
SINA
| $38.5M | 0.29% | +650,000 | New | +$38.5M |
|
57
Arrowhead Research
ARWR
$3.05B
| $35.2M | 0.27% | 1,920,609 +420,609 | +28% | +$7.72M |
|
58
CVS Health
CVS
$92.8B
| $33.7M | 0.25% | 625,000 -305,000 | -33% | -$16.4M |
|
|
RC
59
Ready Capital
RC
$700M
| $32.9M | 0.25% | 2,243,239 +40,000 | +2% | +$587K |
|
60
PTC Therapeutics
PTCT
$3.92B
| $26.3M | 0.2% | 700,000 | – | – |
|
61
Fox Class A
FOXA
$26.6B
| $26M | 0.2% | +709,220 | New | +$26M |
|
62
CRISPR Therapeutics
CRSP
$4.71B
| $25.9M | 0.19% | 725,000 -525,000 | -42% | -$18.8M |
|
|
STML
63
DELISTED
Stemline Therapeutics, Inc.
STML
| $25.7M | 0.19% | +2,000,000 | New | +$25.7M |
|
64
Codexis
CDXS
$246M
| $25.7M | 0.19% | 1,250,000 +95,000 | +8% | +$1.95M |
|
65
Zymeworks
ZYME
$1.12B
| $25.5M | 0.19% | 1,575,000 | – | – |
|
|
QTNT
66
DELISTED
Quotient Limited Ordinary Shares
QTNT
| – | – | -2,400,000 | Closed | -$14.7M |
|
67
Protagonist Therapeutics
PTGX
$3.67B
| $22.5M | 0.17% | 1,790,000 -409,674 | -19% | -$5.15M |
|
|
CCXI
68
DELISTED
ChemoCentryx, Inc.
CCXI
| $20.8M | 0.16% | 1,500,000 +50,000 | +3% | +$695K |
|
|
TECX
69
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $19.8M | 0.15% | 900,000 +250,000 | +38% | +$5.51M |
|
|
PGNX
70
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $19.5M | 0.15% | 4,200,820 | – | – |
|
71
Voyager Therapeutics
VYGR
$186M
| $19.1M | 0.14% | 1,000,158 +91,000 | +10% | +$1.74M |
|
72
Savara
SVRA
$567M
| $17.9M | 0.13% | 2,425,000 | – | – |
|
|
BMS
73
DELISTED
Bemis
BMS
| $17.5M | 0.13% | 316,160 | – | – |
|
|
ZEAL
74
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
| $16.1M | 0.12% | 948,700 +48,700 | +5% | +$829K |
|
|
CLVS
75
DELISTED
Clovis Oncology, Inc.
CLVS
| $14.9M | 0.11% | 600,000 -400,000 | -40% | -$9.93M |
|